20:06 , May 18, 2018 |  BioCentury  |  Finance

Ansun’s China ambitions

The China-heavy syndicate behind Ansun BioPharma Inc.’s $85 million series A round reflects the San Diego-based antiviral company’s long-term plans to penetrate the China market. Sinopharm Healthcare Fund and Lilly Asia Ventures led the round, with...
02:29 , May 18, 2018 |  BC Week In Review  |  Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

Ansun BioPharma Inc. (San Diego, Calif.) raised on May 14 a $85 million series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China,...
15:02 , May 14, 2018 |  BC Extra  |  Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

Ansun BioPharma Inc. (San Diego, Calif.) raised a $85 million series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital,...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

Fludase: Clinical trial data

Data from a transplant patient on a respirator co-infected with influenza and parainfluenza who was treated with a 5-day course of DAS181 under a compassionate use emergency IND showed that the compound reduced oxygen requirement....
07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Amphiregulin (AREG); interleukin-33 (IL-33; NF-HEV)

Autoimmune disease INDICATION: Inflammatory bowel disease (IBD) Mouse studies suggest AREG or IL-33 could help treat IBD. In mice, IL-33 increased AREG expression in gut-associated lymphoid tissue compared with no treatment. In a mouse model of IBD,...
07:00 , Oct 24, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Amphiregulin (AREG); monocyte chemoattractant protein-1 (MCP-1; CCL2); chemokine CC motif ligand...
07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Pulmonary fibrosis Amphiregulin (AREG); epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1); transforming growth factor-b1 (TGFB1) ...
07:00 , Aug 22, 2011 |  BC Week In Review  |  Clinical News

Fludase: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 177 evaluable patients with PCR-confirmed influenza infection showed that once-daily 10 mg DAS181 for 3 days significantly reduced viral load in respiratory secretions, the primary...
08:00 , Feb 21, 2011 |  BC Week In Review  |  Clinical News

Fludase infectious data

NexBio reported data from a single bone marrow transplant patient with PIV-3 infection showing that treatment with DAS181 under emergency-use IND provisions improved the patient's respiratory status within 1 day. By day 3, the patient...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Clinical News

NexBio preclinical data

In mice, 0.06, 0.1 and 0.6 mg/kg once-daily DAS181 for 3 days significantly reduced airway resistance following challenge with methacholine vs. saline-treated controls (p<0.05 for all). Data were presented at the American College of Allergy,...